---
title: "Ascendis Pharma A/S (ASND.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/ASND.US/overview.md"
symbol: "ASND.US"
name: "Ascendis Pharma A/S"
parent: "https://longbridge.com/zh-CN/quote/ASND.US.md"
datetime: "2026-04-15T16:05:58.954Z"
locales:
  - [en](https://longbridge.com/en/quote/ASND.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASND.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASND.US/overview.md)
---

# Ascendis Pharma A/S (ASND.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 生物技术 |
| 交易所 | US Market |
| 地址 | Tuborg Boulevard 12, Hellerup, Capital Region of Denmark, Denmark |
| 官网 | [ascendispharma.com](https://ascendispharma.com) |

## 公司简介

Ascendis Pharma A/S 是一家生物制药公司，专注于开发基于 TransCon 的疗法，以满足欧洲、美国及国际上的未满足医疗需求。该公司提供 SKYTROFA，用于治疗生长激素缺乏的儿童患者；以及 YORVIPATH，这是一种每日一次的皮下注射，用于治疗慢性甲状旁腺功能减退的成人。它还在临床开发中开发三种独立的内分泌罕见疾病产品候选药物，并专注于推进肿瘤治疗候选药物。该公司成立于 2006 年，总部位于丹麦赫勒鲁普

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director |
| Albert Cha | Independent Chairman |
| Scott T. Smith | CFO, Executive VP & Member of Executive Board |
| Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board |
| Michael Wolff Jensen | Executive VP, Chief Legal Officer & Member of the Executive Board |
| Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
| Lars Holtug | Independent Director |
| Lisa Bright Morrison | Independent Director |
| Siham Imani | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| RA Capital Management, L.P. | 16.64% | 2025-12-31 |
| Westfield Capital Management Company, L.P. | 8.39% | 2025-12-31 |
| Avoro Capital Advisors LLC | 8.27% | 2025-12-31 |
| FMR LLC | 6.72% | 2025-12-31 |
| Janus Henderson Group plc | 6.57% | 2025-12-31 |
| T. Rowe Price Group, Inc. | 5.24% | 2025-12-31 |
| Artisan Partners Limited Partnership | 5.22% | 2025-12-31 |
| Capital Research and Management Company | 5.05% | 2025-12-31 |
| Massachusetts Financial Services Company | 3.05% | 2025-12-31 |
| Wellington Management Group LLP | 2.85% | 2025-12-31 |

## 业务构成

| 业务线 | 营收 | 占比 |
|---------|---------|-------|
| 生物技术 | 720132000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Ascendis Pharma A/S Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "生物技术",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地区分布

| 地区 | 营收 | 占比 |
|--------|---------|-------|
| 美国 | 546388000 | 75.87% |
| Europe (excludes Denmark) | 108046000 | 15% |
| 世界其他地区 | 52798000 | 7.33% |
| 丹麦 | 12900000 | 1.79% |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**